Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial

Modified FOLFOX6 plus bevacizumab with and without nivolumab for first-line treatment of metastatic colorectal cancer: phase 2 results from the CheckMate 9X8 randomized clinical trial

Background Standard first-line therapies for metastatic colorectal cancer (mCRC) include fluoropyrimidine-containing regimens with oxaliplatin and/or irinotecan and a biologic agent. Immunotherapy may enhance antitumor activity in combination with standard therapies in patients with mCRC. Here, we p...

Full description

Bibliographic Details
Main Authors:	Takayuki Yoshino, Josep Tabernero, Jin Yao, Amit Mahipal, Eric Chen, Heinz-Josef Lenz, Aparna Parikh, Timothy Larson, Dustin Deming, David R Spigel, Allen L Cohn, Mark Kochenderfer, Elena Elez, Spencer H Shao, Regan Holdridge, Antonio Ucar, Dana Cullen, Edwina Baskin-Bey, Tong Kang, Amy B Hammell
Format:	Article
Language:	English
Published:	BMJ Publishing Group 2024-03-01
Series:	Journal for ImmunoTherapy of Cancer
Online Access:	https://jitc.bmj.com/content/12/3/e008409.full

Similar Items

CheckMate-722: The Rise and Fall of Nivolumab with Chemotherapy in TKI-Refractory EGFR-Mutant NSCLC
by: Lee ATM, et al.
Published: (2023-04-01)

Checkmate to Bioethics?
by: Fabio Alberto Garzón Díaz
Published: (2020-09-01)

Checkmate to Bioethics?
by: Fabio Alberto Garzón Díaz
Published: (2020-09-01)

Safety and efficacy of first-line nivolumab plus ipilimumab alternating with nivolumab monotherapy in patients with advanced renal cell carcinoma: the non-randomised, open-label, phase IIIb/IV CheckMate 920 trial
by: Scott S Tykodi, et al.
Published: (2022-09-01)

A Case of Appendiceal Adenocarcinoma with Clinical Benefit from FOLFOX and Bevacizumab
by: Erin D. Powell, et al.
Published: (2009-07-01)

Cost-effectiveness of FOLFOX6+Bevacizumab Versus FOLFOX6+Cetuximab in Stage IV Colorectal Cancer Patients in Shiraz, Iran
by: Abdosaleh Jafari, et al.
Published: (2023-05-01)

Nivolumab monotherapy or combination with ipilimumab with or without cobimetinib in previously treated patients with pancreatic adenocarcinoma (CheckMate 032)
by: Padmanee Sharma, et al.
Published: (2024-02-01)

Nivolumab adjuvant therapy for esophageal cancer: a review based on subgroup analysis of CheckMate 577 trial
by: Yan Lin, et al.
Published: (2023-10-01)

Biomarker analysis from CheckMate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma
by: Jin Yao, et al.
Published: (2022-03-01)

Checkmate 274 trial: Is Nivolumab the new standard in adjuvant setting for high-risk muscle invasive urothelial carcinoma?
by: Naveen Kumar
Published: (2021-01-01)

Successful Treatment of Metastatic Anal Canal Adenocarcinoma with mFOLFOX6 + Bevacizumab
by: Mototsugu Matsunaga, et al.
Published: (2016-04-01)

Exposure‐response analysis for nivolumab plus ipilimumab combination therapy in patients with advanced hepatocellular carcinoma (CheckMate 040)
by: Bruno Sangro, et al.
Published: (2023-08-01)

Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
by: Asim Amin, et al.
Published: (2018-10-01)

The Efficacy and Safety of Nivolumab Plus mFOLFOX6 in Gastric Cancer with Severe Peritoneal Metastasis
by: Yurika Nakayama, et al.
Published: (2024-01-01)

Correction to: Safety and efficacy of nivolumab in combination with sunitinib or pazopanib in advanced or metastatic renal cell carcinoma: the CheckMate 016 study
by: Asim Amin, et al.
Published: (2019-03-01)

Efficacy of Nivolumab for Head and Neck Cancer Patients with Primary Sites and Histological Subtypes Excluded from the CheckMate-141 Trial
by: Sato Y, et al.
Published: (2020-06-01)

Drug-induced immune-mediated thrombocytopenia due to bevacizumab-FOLFOX therapy: a case report
by: Minna Kim, et al.
Published: (2023-12-01)

Nivolumab plus rucaparib for metastatic castration-resistant prostate cancer: results from the phase 2 CheckMate 9KD trial
by: Jun Li, et al.
Published: (2022-08-01)

Pathological Evaluation of Resected Colorectal Liver Metastases: mFOLFOX6 Plus Bevacizumab versus mFOLFOX6 Plus Cetuximab in the Phase II ATOM Trial
by: Takao Takahashi, et al.
Published: (2022-09-01)

Checkpoint Inhibitors in Checkmating Rare Cancers
by: Sujay Srinivas, et al.
Published: (2021-11-01)

Checkmate to Bioethics? The Case of COVID -19
by: Fabio Alberto Garzón Díaz
Published: (2020-01-01)

Single-cell analysis reveals cellular reprogramming in advanced colon cancer following FOLFOX-bevacizumab treatment
by: Meiling Yang, et al.
Published: (2023-07-01)

Bevacizumab plus FOLFIRI or FOLFOX in chemotherapy-refractory patients with metastatic colorectal cancer: a retrospective study
by: Portales Fabienne, et al.
Published: (2009-09-01)

Long-term follow-up results of nivolumab plus cabozantinib versus sunitinib for advanced renal cell cancer: Checkmate 9ER trial
by: Vivek Tarigopula
Published: (2022-01-01)

Correction: Neoadjuvant nivolumab for patients with resectable HPV-positive and HPV-negative squamous cell carcinomas of the head and neck in the CheckMate 358 trial
Published: (2021-08-01)

First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817
by: Enriqueta Felip, et al.
Published: (2023-02-01)

Retrospective analysis on the clinical efficacy of bevacizumab combined with FOLFOX4 in the first line treatment of metastatic colorectal cancer
by: Eun Mi Lee, et al.
Published: (2017-12-01)

Checkmate with checkpoint inhibitors: New paradigm in immunotherapy
by: Ruby Dhar, et al.
Published: (2023-04-01)

Immunotherapy: an emerging modality to checkmate brain metastasis
by: Aatiya Ahmad, et al.
Published: (2023-07-01)

5-Fluorouracil, leucovorin, and oxaliplatin (mFOLFOX6) plus sunitinib or bevacizumab as first-line treatment for metastatic colorectal cancer: a randomized Phase IIb study
by: Hecht JR, et al.
Published: (2015-06-01)

Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma – Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center
by: Jesko Momotow, et al.
Published: (2019-10-01)

NIVOLUMAB IN THE TREATMENT OF REFRACTORY RECURRENT AND METАSTATIC HEAD AND NECK SQUAMOUS CELL CARCINOMA. THE RESULTS OF A PHASE III CLINICAL TRIAL (CHECKMATE 141)
by: A. M. Mudunov
Published: (2017-11-01)

An open label, safety study of Asian patients with advanced non-small-cell lung cancer receiving second-line nivolumab monotherapy (CheckMate 870)
by: Shun Lu, et al.
Published: (2022-11-01)

A Case of High-Grade Neuroendocrine Carcinoma That Improved with Bevacizumab plus Modified FOLFOX6 as the Fourth-Line Chemotherapy
by: Satoshi Takeuchi, et al.
Published: (2011-05-01)

Combining 1,4-dihydroxy quininib with Bevacizumab/FOLFOX alters angiogenic and inflammatory secretions in ex vivo colorectal tumors
by: Susan A. Kennedy, et al.
Published: (2020-10-01)

Multimodality Treatment of a Colorectal Cancer Stage IV Patient with FOLFOX-4, Bevacizumab, Rigvir Oncolytic Virus, and Surgery
by: Andra Tilgase, et al.
Published: (2018-08-01)

Evaluation of tissue- and plasma-derived tumor mutational burden (TMB) and genomic alterations of interest in CheckMate 848, a study of nivolumab combined with ipilimumab and nivolumab alone in patients with advanced or metastatic solid tumors with high TMB
by: Jie He, et al.
Published: (2023-11-01)

The Woman in White: Marian Halcombe, or Checkmate on Women’s Empowerment
by: Belén Fernández Crespo
Published: (2022-11-01)

Combination therapy to checkmate Glioblastoma: clinical challenges and advances
by: Debarati Ghosh, et al.
Published: (2018-10-01)

616 Pharmacokinetics and safety of a subcutaneous formulation of nivolumab (NIVO SC) monotherapy: updated results from the phase 1/2 CheckMate 8KX study
by: Elizabeth Gibson, et al.
Published: (2023-11-01)